Many startups make the mistake of viewing regulatory affairs – and regulators – as a necessary evil, or barrier to market entry. That can be a huge red flag to investors who know the value of using regulatory as a business and competitive strategy.
What Investors Need to Know About Start-Ups
Startups have different challenges along the road to market release than do the larger, established medical device organizations. As an
Learn More
Regulatory Strategy DOES Make a Difference
I have seen some VERY dysfunctional organizations in my day. No matter the size or how long the company has
Learn More
Looking Beyond the Investor Pitch
As an investor looking into the biotech and medtech industries, you need to know what questions to ask the company
Learn More
Michelle Lott and the leanTeam help clients recognize regulatory and quality issues aren't a "burden" – they are strategic advantages when used properly. The expert team will also strip away any redundant or misdirected activities so you can focus on what really matters:
